Association for Molecular Pathology (AMP)’s Post

🔍 LAST CALL: Help Us Navigate the FDA Rule Changes! 🔍 The #FDARule marks a major shift in how all LDTs are regulated. AMP is gathering input from clinical molecular laboratories to better understand the implications. Your participation in our survey will help us: ✅ Assess the impact on molecular testing and operations ✅ Explore future directions and needs ✅ Determine necessary support and resources 🧬 TAKE OUR SURVEY BY 11:59PM ET TODAY, 10/14: https://lnkd.in/evndPsVZ This survey is open to all, so please spread the word and let’s work together! Your voice matters—thank you for your input! #MolPath #IDTwitter #Genetics #hemepath #bioinformatics #pathology #PGx #precisionmedicine #cytopathology

Be at the forefront of #PGXtesting! We're thrilled to invite you to our #free upcoming webinar, "DPYD Genotyping Recommendations: A Joint Consensus Recommendation of AMP, ACMG, CPIC, CAP, DPWG, ESPT, PharmGKB, and PharmVar”. 📅 Date: October 15, 2024 ⏰ Time: 1:00 PM - 2:00 PM EDT Learn from experts on how these new guidelines can advance DPYD testing across labs and help improve clinical outcomes. 👉 Register now: https://lnkd.in/eC8Fmu3z ACMG - American College of Medical Genetics and Genomics Clinical Pharmacogenetics Implementation Consortium College of American Pathologists (CAP) Apothekersorganisatie KNMP #ESPTsociety PharmGKB PharmVar #molpath #pharmacogenomics #pharmacogenetics

🧬 Attention, Clinical Laboratory Professionals! 🧬 The recent #FDARule marks a significant shift in clinical laboratory regulation and the practice of laboratory medicine. To navigate these changes effectively, the Association for Molecular Pathology (AMP) is conducting a crucial survey aimed at understanding the impact of this rule on molecular laboratory operations. 🌟 Why Your Input Matters 🌟 ▪️ Assess how the FDA Rule affects clinical molecular lab testing and operations ▪️ Explore perceptions about future directions ▪️ Identify necessary resources to support labs This survey is open to all professionals in the field—AMP membership is not required. We encourage you to share this survey with your network to ensure comprehensive feedback. 📊 Take Our Survey by 11:59PM ET, 10/14: https://ow.ly/krRJ50TxAcs Your insights will play a key role in helping AMP advocate for the needs of the laboratory community. Thank you for your valuable contribution! #MolPath #Genetics #hemepath #bioinformatics #pathology #PGx #precisionmedicine #cytopathology

💡 Free Webinar Alert! 💡 Join us next week for the latest Horizons Webinar, "DPYD Genotyping Recommendations: A Joint Consensus Recommendation of AMP, ACMG, CPIC, CAP, DPWG, ESPT, PharmGKB, and PharmVar”. 📆 Date: Tuesday, October 15 🕒 Time: 1:00 PM - 2:00 PM EDT 🔗 FREE Registration: https://ow.ly/eqjo50TGfMi This complimentary #webinar is based on AMP’s new consensus recommendations to aid in the design and validation of clinical DPYD genotyping assays, promote standardization of testing across different laboratories, and improve patient care. The AMP Pharmacogenomics (PGx) Working Group with representation from ACMG - American College of Medical Genetics and Genomics, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists (CAP), Dutch Pharmacogenetics Working Group of Apothekersorganisatie KNMP, European Society for Pharmacogenomics and Personalized Therapy (ESPT), PharmGKB, and PharmVar has developed a series of recommendations to help standardize clinical testing for frequently used genotyping assays. Read the DPYD Recommendations here: https://ow.ly/lYXy50TGfMh #pharmacogenomics #pharmacogenetics #PGXtesting #molpath

Join AMP on 10/7 at 1PM ET for a free webinar, "Embracing Leadership Diversity" with Dr. Maria E. Arcila and Dr. Panieah Terraf. Discuss the unique value of diverse leaders in a genomically driven clinical practice & research future. Register, here: https://ow.ly/KFZA50TxjjX

What does Dr. Rena R. Xian value most about her career in #molpath? Read this month’s AMP member spotlight to find out: https://ow.ly/wo9m50TCF1O #Membership

AMP is pleased to share this survey from our Partner, GenomeWeb. GenomeWeb is conducting a survey of their readers to assess market awareness and utilization of circulating tumor DNA tests to identify or monitor minimal residual disease in patients treated for solid tumor malignancies. This survey should take less than 5 minutes of your time. Responses are confidential and will not be shared. https://lnkd.in/gV7UYCJv

Include a #GraphicalAsbstract with your next submission to JMD! JMD is the official Journal of AMP- submit your work today: https://lnkd.in/ezD37mZx

🚨 Molecular Lab Experts: Your Voice Matters! The FDA's new rule is reshaping clinical laboratory regulations, and it's critical we understand its impact. The Association for Molecular Pathology (AMP) is conducting a survey to gather insights on how this change is affecting molecular laboratory developed tests (#LDTs) in #CLIA settings. Whether you're an AMP member or not, your expertise is invaluable in shaping the future. Please take a moment to share your insights and experiences. 🧬 Take the Survey Here: https://lnkd.in/evndPsVZ #MolPath #IDTwitter #Genetics #hemepath #bioinformatics #pathology #PGx #precisionmedicine #cytopathology